FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3166525692> ?p ?o ?g. }

• W3166525692 endingPage "e21546" @default.
• W3166525692 startingPage "e21546" @default.
• W3166525692 abstract "e21546 Background: Four independent groups have demonstrated that the pre-treatment gut microbiome of cancer patients impacts the subsequent response to Immune Checkpoint Inhibitor (ICIs) therapy [1-4]. However, the patient’s outcome was linked to different bacteria in each study, which has limited the development of drug response biomarkers and clinic-first design of novel microbiome-based therapeutics. Methods: The Cambridge (UK) MELRESIST study includes a cohort of advanced melanoma patients receiving approved ICIs. Pretreatment stool samples from MELRESIST were analysed by Microbiotica using shotgun metagenomic sequencing. Microbiotica’s platform comprises the world’s leading Reference Genome Database to give the most comprehensive and precise mapping of the gut microbiome. Results: MELRESIST samples showed an overall difference in the microbiome composition between advanced melanoma patients and healthy donors, but not between patients who did or did not respond to ICIs. However, we did identify a discrete microbiome signature that differentiated responders and non-responders with an accuracy of 93%. We extended this signature by reanalysing three published melanoma cohorts [1-3] using the Microbiotica platform, and a propriety bioinformatic model. The resultant bacterial signature was very accurate at predicting response in all 4 published studies combined (91%), and each cohort individually (82-100%). We validated the model using independent validation cohorts and the signature using lung and renal cancer studies [4]. At the core of our microbiome signature was 9 bacteria most significantly associated with ICI efficacy. All 9 were overrepresented in patients who responded to immunotherapy suggesting high abundance of these bacteria is a central driver of ICI response. A consortium comprised of all 9 strains had very potent anti-tumor efficacy in a cancer syngeneic mouse model. The bacteria also demonstrate multiple interactions with primary human immune cells in vitro leading to dendritic cells activation, Cytotoxic T lymphocyte activation and tumor cell killing. These validate the potential of this consortium as a novel therapy for use in combination with ICIs. Conclusions: We have identified a unique microbiome signature predictive of ICI response in 4 independent melanoma cancer cohorts. This removes a major challenge to the field, and could represent a new highly accurate biomarker with clinical application. Nine core bacteria appear to be driving response, and demonstrate anti-tumor activity in vivo and in vitro. This consortium holds great potential as a co-therapy with ICIs. References:1 Matson V et al, Science (2018) 359:104; 2 Gopalakrishnan V et al, Science (2018) 359:97; 3 Frankel AE et al, Neoplasia (2017) 19:848; 4 Routy B et al, Science (2018) 359:91." @default.
• W3166525692 created "2021-06-22" @default.
• W3166525692 creator A5010410893 @default.
• W3166525692 creator A5011223977 @default.
• W3166525692 creator A5025386235 @default.
• W3166525692 creator A5029527227 @default.
• W3166525692 creator A5041987249 @default.
• W3166525692 creator A5049639550 @default.
• W3166525692 creator A5050346632 @default.
• W3166525692 creator A5058556459 @default.
• W3166525692 creator A5070314798 @default.
• W3166525692 creator A5081305393 @default.
• W3166525692 creator A5082780523 @default.
• W3166525692 creator A5086349623 @default.
• W3166525692 creator A5087905744 @default.
• W3166525692 date "2021-05-20" @default.
• W3166525692 modified "2023-09-27" @default.
• W3166525692 title "Using precision microbiome profiling to develop a biomarker for immune checkpoint inhibitor response and a novel therapeutic." @default.
• W3166525692 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.e21546" @default.
• W3166525692 hasPublicationYear "2021" @default.
• W3166525692 type Work @default.
• W3166525692 sameAs 3166525692 @default.
• W3166525692 citedByCount "2" @default.
• W3166525692 countsByYear W31665256922022 @default.
• W3166525692 countsByYear W31665256922023 @default.
• W3166525692 crossrefType "journal-article" @default.
• W3166525692 hasAuthorship W3166525692A5010410893 @default.
• W3166525692 hasAuthorship W3166525692A5011223977 @default.
• W3166525692 hasAuthorship W3166525692A5025386235 @default.
• W3166525692 hasAuthorship W3166525692A5029527227 @default.
• W3166525692 hasAuthorship W3166525692A5041987249 @default.
• W3166525692 hasAuthorship W3166525692A5049639550 @default.
• W3166525692 hasAuthorship W3166525692A5050346632 @default.
• W3166525692 hasAuthorship W3166525692A5058556459 @default.
• W3166525692 hasAuthorship W3166525692A5070314798 @default.
• W3166525692 hasAuthorship W3166525692A5081305393 @default.
• W3166525692 hasAuthorship W3166525692A5082780523 @default.
• W3166525692 hasAuthorship W3166525692A5086349623 @default.
• W3166525692 hasAuthorship W3166525692A5087905744 @default.
• W3166525692 hasConcept C121608353 @default.
• W3166525692 hasConcept C126322002 @default.
• W3166525692 hasConcept C143121216 @default.
• W3166525692 hasConcept C143998085 @default.
• W3166525692 hasConcept C203014093 @default.
• W3166525692 hasConcept C2777658100 @default.
• W3166525692 hasConcept C2777701055 @default.
• W3166525692 hasConcept C2781197716 @default.
• W3166525692 hasConcept C502942594 @default.
• W3166525692 hasConcept C54355233 @default.
• W3166525692 hasConcept C60644358 @default.
• W3166525692 hasConcept C70721500 @default.
• W3166525692 hasConcept C71924100 @default.
• W3166525692 hasConcept C72563966 @default.
• W3166525692 hasConcept C86803240 @default.
• W3166525692 hasConceptScore W3166525692C121608353 @default.
• W3166525692 hasConceptScore W3166525692C126322002 @default.
• W3166525692 hasConceptScore W3166525692C143121216 @default.
• W3166525692 hasConceptScore W3166525692C143998085 @default.
• W3166525692 hasConceptScore W3166525692C203014093 @default.
• W3166525692 hasConceptScore W3166525692C2777658100 @default.
• W3166525692 hasConceptScore W3166525692C2777701055 @default.
• W3166525692 hasConceptScore W3166525692C2781197716 @default.
• W3166525692 hasConceptScore W3166525692C502942594 @default.
• W3166525692 hasConceptScore W3166525692C54355233 @default.
• W3166525692 hasConceptScore W3166525692C60644358 @default.
• W3166525692 hasConceptScore W3166525692C70721500 @default.
• W3166525692 hasConceptScore W3166525692C71924100 @default.
• W3166525692 hasConceptScore W3166525692C72563966 @default.
• W3166525692 hasConceptScore W3166525692C86803240 @default.
• W3166525692 hasIssue "15_suppl" @default.
• W3166525692 hasLocation W31665256921 @default.
• W3166525692 hasOpenAccess W3166525692 @default.
• W3166525692 hasPrimaryLocation W31665256921 @default.
• W3166525692 hasRelatedWork W2334280095 @default.
• W3166525692 hasRelatedWork W2895744166 @default.
• W3166525692 hasRelatedWork W2937519691 @default.
• W3166525692 hasRelatedWork W2998626232 @default.
• W3166525692 hasRelatedWork W3013039076 @default.
• W3166525692 hasRelatedWork W3110077847 @default.
• W3166525692 hasRelatedWork W3119233406 @default.
• W3166525692 hasRelatedWork W4206284710 @default.
• W3166525692 hasRelatedWork W4289517314 @default.
• W3166525692 hasRelatedWork W4301368631 @default.
• W3166525692 hasVolume "39" @default.
• W3166525692 isParatext "false" @default.
• W3166525692 isRetracted "false" @default.
• W3166525692 magId "3166525692" @default.
• W3166525692 workType "article" @default.